IN THE CLAIMS

Please amend the claims as follows:

Claims 1-46 (Cancelled)

Claim 47 (Currently Amended): A method of expressing a selected polynucleotide in a mammalian cell, comprising

providing an expression construct, which comprises (A) an HIV-2 promoter sequence operably linked to a selected polynucleotide; and (B) an inducible promoter sequence operably linked to a polynucleotide encoding the HIV tat transactivating factor, which binds to and activates said HIV-2 promoter;

introducing said expression construct into the mammalian cell; and

subjecting said cell to conditions which activate said inducible promoter thereby resulting in the expression of said selected polynucleotide.

Claim 48 (Previously Presented): The method of Claim 47, wherein said inducible promoter is a heat shock promoter.

Claim 49 (Previously Presented): The method of Claim 47, wherein said conditions which activate said heat shock promoter comprises subjecting the cell to hyperthermic conditions.

Claim 50 (Currently Amended): The method of ~~Claim 47~~ Claim 48, wherein said heat shock promoter is selected from the group consisting of an HSP70 promoter, an HSP90 promoter, an HSP60 promoter, an HSP27 promoter, an HSP25 promoter, and a ubiquitin promoter.

Claim 51 (Previously Presented): The method of Claim 47, wherein the expression construct further comprises, in a 5' to 3' orientation, a second promoter sequence operably linked to a selectable marker gene between (A) and (B).

Claim 52 (Previously Presented):The method of Claim 47, wherein said selected polynucleotide results in the production of a polypeptide, protein, ribozyme, or an antisense molecule.

Claim 53 (Previously Presented): The method of Claim 47, wherein the expression construct further comprises a second selected polynucleotide operably linked to said HIV-2 promoter and an internal ribosome entry site positioned between the two selected polynucleotides.

Claim 54 (Previously Presented): The method of Claim 47, wherein said second selected polynucleotide results in the production of a polypeptide, protein, ribozyme, or an antisense molecule.

Claim 55 (Previously Presented): The method of Claim 47, wherein the introduction of said expression construct into the cell is mediated by a delivery vehicle selected from the group consisting of liposomes, retroviruses, adenoviruses, adeno-associated viruses, lentiviruses, herpes simplex viruses, and vaccinia viruses.

Claim 56 (Previously Presented): The method of Claim 47, wherein the introduction of said expression construct occurs *in vitro*.

Claim 57 (Previously Presented): The method of Claim 47, wherein the introduction of said expression construct occurs *in vivo* or *ex vivo*.

Claim 58 (New): The method of Claim 47, wherein the inducible promoter is a CMV promoter.

Claim 59 (New) A method of expressing a selected polynucleotide in a mammalian cell, comprising

providing an expression construct, which comprises (A) an HIV-1 promoter sequence operably linked to a selected polynucleotide; and (B) an inducible promoter sequence

operably linked to a polynucleotide encoding the HIV tat transactivating factor, which binds to and activates said HIV-1 promoter;

introducing said expression construct into the mammalian cell; and

subjecting said cell to conditions which activate said inducible promoter thereby resulting in the expression of said selected polynucleotide.

Claim 60 (New): The method of Claim 59, wherein said inducible promoter is a heat shock promoter.

Claim 61 (New): The method of Claim 59, wherein said conditions which activate said heat shock promoter comprises subjecting the cell to hyperthermic conditions.

Claim 62 (New): The method of Claim 60, wherein said heat shock promoter is selected from the group consisting of an HSP70 promoter, an HSP90 promoter, an HSP60 promoter, an HSP27 promoter, an HSP25 promoter, and a ubiquitin promoter.

Claim 63 (New): The method of Claim 59, wherein the expression construct further comprises, in a 5' to 3' orientation, a second promoter sequence operably linked to a selectable marker gene between (A) and (B).

Claim 64 (New):The method of Claim 59, wherein said selected polynucleotide results in the production of a polypeptide, protein, ribozyme, or an antisense molecule.

Claim 65 (New): The method of Claim 59, wherein the expression construct further comprises a second selected polynucleotide operably linked to said HIV-1 promoter and an internal ribosome entry site positioned between the two selected polynucleotides.

Claim 66 (New): The method of Claim 59, wherein said second selected polynucleotide results in the production of a polypeptide, protein, ribozyme, or an antisense molecule.

Claim 67 (New): The method of Claim 59, wherein the introduction of said expression construct into the cell is mediated by a delivery vehicle selected from the group

consisting of liposomes, retroviruses, adenoviruses, adeno-associated viruses, lentiviruses, herpes simplex viruses, and vaccinia viruses.

Claim 68 (New): The method of Claim 59, wherein the introduction of said expression construct occurs *in vitro*.

Claim 69 (New): The method of Claim 59, wherein the introduction of said expression construct occurs *in vivo* or *ex vivo*.

Claim 70 (New): The method of Claim 59, wherein the inducible promoter is a CMV promoter.